Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584974 · ClinicalTrials.gov registry record · Phase 2
A Safety, Efficacy and Tolerability Study of SEP-225289
A Phase 2 study of Depressive Disorder, Major, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 523
- Enrollment target
- 20
- Study locations
NCT00584974: Completed Phase 2 study of Depressive Disorder, Major, sponsored by Sumitomo Pharma America.
NCT00584974 is a Phase 2 study of Depressive Disorder, Major that has completed, run by Sumitomo Pharma America. The registered enrollment target is 523 participants, above the 232-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (125% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00584974, a Phase 2 study of Depressive Disorder, Major, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 523 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder
Conditions Studied
Interventions
- DRUG placebo
- DRUG SEP-225289
- DRUG Venlafaxine
Study Locations (20)
California
- - Arcadia
- - Beverly Hills
- - Costa Mesa
- - Garden Grove
- - Glendale
- - Irvine
- - Lafayette
- - Oceanside
- - San Diego
- - Upland
Florida
- - Bradenton
- - Fort Myers
- - Jacksonville
- - Lauderhill
- - Maitland
- - North Miami
Colorado
- - Denver
- - Denver
Arkansas
- - Little Rock
Connecticut
- - New Britain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 523 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00584974 record still lists
NCT00584974 is an interventional study that assigns participants to a tested intervention. The registered 523 participants enrollment target is mid-sized for trials with a published cap, above the 232-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (125% higher).
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00584974 names 20 study sites across 5 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00584974 about?
NCT00584974 is a clinical study titled "A Safety, Efficacy and Tolerability Study of SEP-225289". To determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder
What is the current status of trial NCT00584974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 523 participants. The study started on 2007-12. Estimated completion is 2009-05.
What conditions does trial NCT00584974 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT00584974?
The interventions under investigation include: placebo (DRUG), SEP-225289 (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00584974?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00584974 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00584974's enrollment target sits among peer trials
523 9th of 52 higher than 44 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03526835 · 523 participants · Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
- NCT07158814 · 524 participants · Phase 4
Safety of RSV Preventive Monoclonal Antibody
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia